Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future.

ABSTRACT: Belatacept is the first costimulatory blockade agent clinically approved for transplant immunosuppression. Although more than 10 years of study have demonstrated that belatacept offers superior long-term renal allograft and patient survival compared to conventional calcineurin inhibitor (CNI)-based immunosuppression regimens, the clinical adoption of belatacept has continued to lag because of concerns of an early risk of acute cellular rejection (ACR) and various logistical barriers to its administration. In this review, the history of the clinical development of belatacept is examined, along with the findings of the seminal BENEFIT and BENEFIT-EXT trials culminating in the clinical approval of belatacept. Recent efforts to incorporate belatacept into novel CNI-free immunosuppression regim

SUBMITTER: Kitchens WH 

PROVIDER: S-EPMC10719580 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature